TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Improvement in Investigator's Static Global Assessment (ISGA) Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of patients prescribed recommended antimalarial drug
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Propofol effect-site concentration (Ce)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy Identifying Taught Words - Syntactic Condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy Identifying Taught Words - Semantic Condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy Identifying Taught Words - Combined Condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Adverse Drug Reactions of Major Investigation Items
Endpoint domain: Adverse events/effects
Primary endpoint: circulating miR-218 as biomarker for ALS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colon cleansing level score for PCCE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grading of visual interference from bubbles in the colon for PCCE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Goal Performance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Complete therapeutic sequence without significant complication
Endpoint domain: Adverse events/effects
Primary endpoint: Successful generation of pancreatic organoids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of the fibrosis in the Left Atrium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left Atrial Emptying Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urinary Excretion of Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Fractional Excretion of Uric Acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Freedom from clinical driven Target Lesion Revascularisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Induction of tumor and prostate-specific immunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of enteric zoster
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of dangerous street crossing decisions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Street crossing decision safety scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Aqueous cytokine Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline of the Sum Score of Local Eczema Rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Adverse event and adverse drug reaction
Endpoint domain: Adverse events/effects
Primary endpoint: mean change from baseline in BCVA letters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean retinal thickness change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Placebo-Corrected Change from Baseline in QT Interval Corrected for Individual Heart Rate (QTcI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain at 24 hour postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-month functional independence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in pediatric asthma quality of life questionnaire score (PAQLQ score)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Completion of an advance directive
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of Subjects With VMA/VMT Resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Opiate Requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Relapse
Endpoint domain: Mortality/survival
Primary endpoint: Safety and tolerability of SNS-032
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with block in the proximal conduction system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Scale for the Assessment of Negative Symptoms (SANS) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Z-Scores for Composite Cognitive Primary Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Molecular changes in melanoma tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: long-term adverse outcomes of HIV infection
Endpoint domain: Adverse events/effects
Primary endpoint: complications of antiretroviral therapy (ART)
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of pregabalin
Endpoint domain: Adverse events/effects
Primary endpoint: ADHD Rating Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PQ interval analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to first MACE-4 event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of Fungal Infection
Endpoint domain: Adverse events/effects
Primary endpoint: JL1 expression in B-cell Acute Lymphoblastic Leukemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum value of summation of predicted forces in all trunk muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maximum spinal load at the lowest level of lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Angina Class Variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of sessions attended
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of Patients With Platelet Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Transplant-related Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Reduction of the Perioral Dermatitis Severity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Hallucination change score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency subscale of Auditory Hallucinations Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of care dependency
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Composite mortality and morbidity score
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of acute urinary and rectal toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Minimal residual disease (MRD) negative status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gene-expression in PBMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Patient Described Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Patient described anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in patient described satisfaction with ongoing treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in patient described pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Post Procedure Pain on the Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Referral rate of patients
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Plasma Tenofovir Area Under the Curve (AUC0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tenofovir-diphosphate (TFV-DP) in PBMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor Coordination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal Layers' Development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Standard Alcoholic Drinks Consumed Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urogenital CT Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Grade 3, 4, or 5 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity of Umbilical cord length index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax (Maximum baseline-adjusted nicotine plasma concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCnic0-60
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in APACHE II score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional magnetic resonance imaging (MRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in treatment satisfaction scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: iAUC for each AVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for each AVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax for each AVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T1/2 for each AVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Latent HIV Reservoir Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Reduction From Baseline in Menstrual Blood Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discrimination between healthy individuals and those with multiple sclerosis (MS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline AMH Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Baseline tissue oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole Genome DNA Methylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Dose limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Vanderbilt ADHD Parent Rating Scales (VADPRS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Behavior Rating Inventory of Executive Functioning (BRIEF)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time to failure of strategy
Endpoint domain: Mortality/survival
Primary endpoint: Frequency and Severity of Solicited Local and Systemic AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency and Severity of Unsolicited AEs and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting 7 Day Point Prevalence Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Perceived Stress Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Depressive Symptoms Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Frailty screening performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of BICLA response at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity for electrographic seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of false alarms by study device per hour
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in ASM mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in ASM proliferation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in ASM migration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in chemokine release
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion of patients with syncope recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Body composition and Anthropometric parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose metabolism parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lipid metabolism biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline ROTEM® measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Biventricular pacing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clearance of Actinic Keratoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Normal fetal growth (velocity) and size for gestational age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Individualized standard for fetal growth potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete stone clearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Energy intake at ad-libitum meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Correct identification of emotional pictures
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum Tolerated Dose of Lapatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes of MRI ADC value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psoriasis Area and Severity Index-75 reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of missed working days due to psoriasis
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: safety and tolerability assessed by analyzing serious and non-serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Total Myocardial Oxygen Consumption (MVO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total Myocardial Fatty Acid (FA) Utilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total Myocardial Fatty Acid (FA) Oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Performance in motor memory consolidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: repetition of DSH
Endpoint domain: Adverse events/effects
Primary endpoint: Need for Recovery
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Percentage of participants who reported any serious infections
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants who reported any adverse drug reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants who reported any infections
Endpoint domain: Adverse events/effects
Primary endpoint: Change in sweat chloride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: evoked EMG amplitude of facial nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Perioperative inflammatory response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: In-segment percent diameter stenosis (%DS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of baseline regulatory T cells (Tregs) at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of baseline regulatory T cells (Tregs) at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Scores on rating scales for depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Scores on rating scales for symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity participation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: hepatic morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychological adjustment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Freedom from structural valve deterioration (SVD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Level of TNF-α
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum Level of IL1b
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum Level of IL6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum Level of IFN-gamma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of symptomatic and/or persistent re-occurrences of atrial arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to first re-occurrence of first symptomatic or persistent atrial arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Radioaerosol deposition index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse-free Survival (RFS)
Endpoint domain: Mortality/survival
Primary endpoint: Clinical performance of MicroPhage test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of sentinel lymph node dissection
Endpoint domain: Adverse events/effects
Primary endpoint: Left Ventricular Contractility at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Right Ventricular Structure at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Day 3 delta SOFA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EMP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline of thickening fraction of diaphragm muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects With ≥50% Reduction in Low Back Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visceral Adiposity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Echocardiographic parameters of the right ventricle (RV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gene expression of biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects Losing at Least 5% of Baseline Body Weight at Week 56
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: overall survival outcome
Endpoint domain: Mortality/survival
Primary endpoint: Disease-free survival outcome
Endpoint domain: Mortality/survival
Primary endpoint: Changes in hematology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in immune and inflammatory states
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Photographic Haze Reduced to Grade 0 or Down 2 Steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant Improvement of Macular Edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Posterior Shoulder Tightness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Induction of cellular immunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: steady state viremia (viral set point)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Social Skills Group Questionnaire (SSGQ)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Appetite sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma ghrelin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma GLP-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes